Found: 20
Select item for more details and to access through your institution.
The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2879, doi. 10.1007/s00262-023-03465-9
- By:
- Publication type:
- Article
A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2889, doi. 10.1007/s00262-022-03352-9
- By:
- Publication type:
- Article
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2905, doi. 10.1007/s00262-023-03374-x
- By:
- Publication type:
- Article
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2919, doi. 10.1007/s00262-023-03385-8
- By:
- Publication type:
- Article
Murine regulatory T cells utilize granzyme B to promote tumor metastasis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2927, doi. 10.1007/s00262-023-03410-w
- By:
- Publication type:
- Article
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2939, doi. 10.1007/s00262-023-03444-0
- By:
- Publication type:
- Article
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2949, doi. 10.1007/s00262-023-03466-8
- By:
- Publication type:
- Article
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2961, doi. 10.1007/s00262-023-03469-5
- By:
- Publication type:
- Article
Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2971, doi. 10.1007/s00262-023-03473-9
- By:
- Publication type:
- Article
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2991, doi. 10.1007/s00262-023-03467-7
- By:
- Publication type:
- Article
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3003, doi. 10.1007/s00262-023-03471-x
- By:
- Publication type:
- Article
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3013, doi. 10.1007/s00262-023-03470-y
- By:
- Publication type:
- Article
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3029, doi. 10.1007/s00262-023-03474-8
- By:
- Publication type:
- Article
IL-36α inhibits melanoma by inducing pro-inflammatory polarization of macrophages.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3045, doi. 10.1007/s00262-023-03477-5
- By:
- Publication type:
- Article
Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3063, doi. 10.1007/s00262-023-03478-4
- By:
- Publication type:
- Article
TGF-β1 mediates tumor immunosuppression aggravating at the late stage post-high-light-dose photodynamic therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3079, doi. 10.1007/s00262-023-03479-3
- By:
- Publication type:
- Article
The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3097, doi. 10.1007/s00262-023-03483-7
- By:
- Publication type:
- Article
Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3111, doi. 10.1007/s00262-023-03472-w
- By:
- Publication type:
- Article
Tumor immunology meets oncology (TIMO) XVI, July 07–09 2022 in Halle/Saale, Germany.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3125, doi. 10.1007/s00262-023-03468-6
- By:
- Publication type:
- Article
Considerations regarding the tumor-suppressor role of naringenin as a novel agent for the treatment of oral squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3133, doi. 10.1007/s00262-023-03452-0
- By:
- Publication type:
- Article